Gilead Sciences

BioPharma, Pharma

Gilead Sciences Gets a Shot at Next-Gen Cell Therapy With $325M Arcellx Alliance

In partnering with clinical-stage Arcellx, Gilead Sciences gains the opportunity to develop a cell therapy for multiple myeloma that could offer advantages over currently available therapies for the blood cancer. The deal announced Friday came as Arcellx reported additional data during the annual meeting of the American Society of Hematology that showed continued durability of the cell therapy.